Literature DB >> 19025432

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Polly E Kintzel1, Sandra L Chase, Lisa M Schultz, Timothy J O'Rourke.   

Abstract

Prostate cancer is the leading cancer diagnosis and second leading cause of cancer-related mortality for men in the United States. Due to the increased prevalence of prostate cancer in men older than 50 years, men at risk for prostate cancer represent the same population of men who are at greatest risk for metabolic syndrome, diabetes mellitus, and coronary artery disease (CAD). In addition to risk factors for CAD that are applicable to the general population, men with prostate cancer can be at increased risk for CAD due to long-term androgen deprivation therapy (ADT) administered as treatment for prostate cancer. Men undergo ADT by medical (drug therapy) or surgical (castration) means. Luteinizing hormone-releasing hormone (LHRH) agonists are the primary drug therapies used for ADT. Commercially available LHRH agonists are goserelin, histrelin, leuprolide, and triptorelin. Body composition changes, hyperlipidemia, insulin resistance, metabolic syndrome, and acute coronary syndrome are all reported adverse effects of ADT, which are consequences of reduced levels of circulating testosterone. Metabolic and body composition changes associated with ADT arise within months of beginning medical ADT and persist after discontinuation of therapy. To better understand the increased risk of metabolic syndrome, diabetes, and heart disease in patients undergoing ADT for prostate cancer, we performed a MEDLINE search (1986-2008) to identify pertinent studies and reports. Additional citations were obtained from the articles retrieved from the literature search. We found that the increased risk for serious cardiovascular disease becomes evident within months of beginning ADT. Pharmacists should provide counseling to these patients on primary disease prevention. Men receiving ADT should be monitored routinely for signs and symptoms of metabolic syndrome, diabetes, and CAD. Healthy lifestyle practices should be encouraged, and physical therapy should be considered for these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19025432     DOI: 10.1592/phco.28.12.1511

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  38 in total

1.  Can alternative medicine do better than placebo?: Does it even matter?

Authors:  Mark A Moyad
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

Review 2.  Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies.

Authors:  Myrto Boukovala; Nicholas Spetsieris; Eleni Efstathiou
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

3.  Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study.

Authors:  Harmanpreet Kaur; D Robert Siemens; Angela Black; Sylvia Robb; Spencer Barr; Charles H Graham; Maha Othman
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

4.  Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

Authors:  Howard Huaihan Pai; Tom Pickles; Mira Keyes; Stuart Jones; Rachel E McDonald; Mary Lesperance; Eric Berthelet
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

Review 5.  Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials.

Authors:  Freerk T Baumann; Eva M Zopf; Wilhelm Bloch
Journal:  Support Care Cancer       Date:  2011-10-12       Impact factor: 3.603

Review 6.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

7.  Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.

Authors:  Lauren P Wallner; Renyi Wang; Steven J Jacobsen; Reina Haque
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-04       Impact factor: 4.254

8.  Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.

Authors:  Jingjing Cai; Yuan Hong; Chunyan Weng; Chen Tan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-21       Impact factor: 4.733

9.  Early life exposure to the 1918 influenza pandemic and old-age mortality by cause of death.

Authors:  Mikko Myrskylä; Neil K Mehta; Virginia W Chang
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

10.  Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors.

Authors:  Gregory P Beehler; Michael Wade; Borah Kim; Lynn Steinbrenner; Laura O Wray
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.